Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430654 | 0.87 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL2428441 | 0.85 | DGAT1 (0.34) | DGAT1ERN1 | |
| SCHEMBL31056114 | 0.83 | NPC1 (0.32) | DGAT1 | |
| SCHEMBL2425423 | 0.83 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL6525558 | 0.83 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL20488714 | 0.81 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL2425101 | 0.81 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL15809068 | 0.80 | HSD17B10 (0.35) | DGAT1 | |
| SCHEMBL2429629 | 0.80 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL31038888 | 0.79 | NPC1 (0.36) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4654964-A1 | SULFONE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF | The Rockefeller University (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025090658-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2024178390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024158875-A1 | SULFONE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 2024-08-02 | — | — | WO | disclosed |
| US-8026257-B2 | Substituted heterocyclic ethers and their use in CNS disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026257-B2 | Substituted heterocyclic ethers and their use in CNS disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| WO-2009009411-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | CDK2, CDK20, CDK1 | DGAT1 4494/4885ERN1 1389/4885 |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | DGAT1 2501/4885ERN1 685/4885 |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | CNR1, CNR2, PMP22 | DGAT1 1965/4885ERN1 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.